Patents by Inventor Craig W. Beattie
Craig W. Beattie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10196428Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions related to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds to cancer cell.Type: GrantFiled: August 9, 2016Date of Patent: February 5, 2019Inventors: Tapas K. Das Gupta, Craig W. Beattie
-
Publication number: 20170174729Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides.Type: ApplicationFiled: August 9, 2016Publication date: June 22, 2017Inventors: Tapas K. Das Gupta, Craig W. Beattie
-
Patent number: 9598470Abstract: The present invention relates to compositions and methods comprising chemopreventive agents that may be cupredoxin(s) or variants, derivatives and structural equivalents of cupredoxins, and at least one other chemopreventive agent. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The compositions of the invention may be used to prevent or inhibit the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.Type: GrantFiled: May 18, 2009Date of Patent: March 21, 2017Inventors: Craig W. Beattie, Tohru Yamada, Tapas K. Das Gupta
-
Patent number: 9434770Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides. The modified cupredoxin derived peptides can be used in methods to treat mammals for cancer, conditions related to inappropriate angiogenesis, viral and bacterial infections, and specifically HIV and malaria, conditions related to ephrin signaling, and to deliver cargo compounds, including diagnostic compounds, to cancer cells.Type: GrantFiled: February 19, 2009Date of Patent: September 6, 2016Inventors: Tapas K Das Gupta, Craig W Beattie
-
Patent number: 9107881Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.Type: GrantFiled: February 11, 2013Date of Patent: August 18, 2015Assignee: The Board of Trustees of the University of IllinoisInventors: Rajeshwari R Mehta, Brad N Taylor, Tohru Yamada, Craig W Beattie, Tapas K Das Gupta, Ananda M Chakrabarty
-
Patent number: 8372962Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.Type: GrantFiled: February 27, 2012Date of Patent: February 12, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty
-
Publication number: 20120196805Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.Type: ApplicationFiled: February 27, 2012Publication date: August 2, 2012Inventors: Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty
-
Patent number: 8124055Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.Type: GrantFiled: June 3, 2009Date of Patent: February 28, 2012Assignee: The Board of Trustees of the University of IllinoisInventors: Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty
-
Publication number: 20100093057Abstract: The present invention relates to compositions and methods comprising chemopreventive agents that may be cupredoxin(s) or variants, derivatives and structural equivalents of cupredoxins, and at least one other chemopreventive agent. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The compositions of the invention may be used to prevent or inhibit the development of premalignant lesions in mammalian cells, tissues and animals, and thus prevent cancer.Type: ApplicationFiled: May 18, 2009Publication date: April 15, 2010Inventors: Craig W. Beattie, Tohru Yamada, Tapas K. Das Gupta
-
Publication number: 20100008919Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.Type: ApplicationFiled: June 3, 2009Publication date: January 14, 2010Inventors: Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty
-
Publication number: 20090286719Abstract: The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides.Type: ApplicationFiled: February 19, 2009Publication date: November 19, 2009Inventors: Tapas K. Das Gupta, Craig W. Beattie
-
Patent number: 7556810Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.Type: GrantFiled: July 19, 2006Date of Patent: July 7, 2009Assignee: The Board of Trustees of the University of IlinoisInventors: Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty
-
Publication number: 20080103087Abstract: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or structural equivalents of cupredoxins, which retain the ability to inhibit angiogenesis in mammalian cells, tissues or animals. These compositions may be peptides or pharmaceutical compositions, among others. The compositions of the invention may be used to treat any pathological condition that has as a symptom or cause, inappropriate angiogenesis, and particularly inappropriate angiogenesis related to tumor development.Type: ApplicationFiled: July 19, 2006Publication date: May 1, 2008Inventors: Rajeshwari R. Mehta, Brad N. Taylor, Tohru Yamada, Craig W. Beattie, Tapas K. Das Gupta, Ananda M. Chakrabarty
-
Patent number: 4618230Abstract: A visual stimulator for light stimulation of a subject's eyes to obtain electroretinogram, electro-oculogram or visually evoked potential responses. The stimulator comprises a light directing means for directing light from a light source into the subject's eyes, attenuator means for selectably attenuating the light source, photodetector means for producing an output signal representative of the radiant energy directed into the subject's eyes and signal processing means for receiving and processing the output signal to derive therefrom further output signals representative of the radiometric or photometric characteristics of said radiant energy. A light shutter comprising first and second shutter leaves affixed to the shafts of first and second galvanometers is also provided. The shutter leaves are positioned for pivotal movement with the galvanometer shafts to attenuate light passing between the shutter leaves.Type: GrantFiled: June 24, 1982Date of Patent: October 21, 1986Assignee: Vancouver General HospitalInventors: John Ens, James A. McEwen, Craig W. Beattie